ArticleNature communications2026
DiscERN: an automated genome mining tool for the discovery of evolutionarily related natural products.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DiscERN: an automated genome mining tool for the discovery of evolutionarily related natural products.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Targeted genome mining to expand known families of natural products is a powerful strategy for discovering bioactive compounds, yet it remains a significant bioinformatics challenge. While tools exist for de novo biosynthetic gene cluster identification and large-scale unsupervised clustering, dedicated methods for the targeted, hypothesis-driven expansion of user-defined BGC families are lacking. Here, we present DiscERN (Discoverer of Evolutionarily Related Natural products), a user-friendly tool designed to address this gap. DiscERN leverages a multi-modal ensemble method that integrates four complementary algorithms classifying biosynthetic gene clusters based on Pfam content, sequence homology, and predicted product structure. This approach allows users to strategically balance discovery sensitivity with predictive precision to suit diverse research goals. We demonstrate DiscERN's utility by applying it to a large collection of actinomycete genomes and validating its predictive power through the successful isolation of discomycin A, a new calcium-dependent lipopeptide antibiotic, from a silent biosynthetic gene cluster. DiscERN provides a robust and accessible platform that streamlines the path from genomic data to a prioritised list of candidate biosynthetic gene clusters, effectively bridging the gap between in silico prediction and bioactive compound discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.